Thus, miR‐126 has a positive correlation with its host gene, EGFL7, and an inverse correlation with its target, p85β, in CLL patients regardless of the change in expression postibrutinib therapy. The gene discussed is PIK3R2; the disease is B-cell chronic lymphocytic leukemia.